Spero Therapeutics, Inc. Common Stock (SPRO)
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for bacterial infectious diseases. The company's portfolio includes innovative antibiotics aimed at treating multi-drug resistant infections, addressing significant unmet medical needs in infectious disease care.
Company News
Spero Therapeutics announced interim leadership changes, including the appointment of Esther Rajavelu as Interim President and CEO, and Frank Thomas as Chairman of the Board. The company also provided updates on the Phase 3 PIVOT-PO trial of Tebipenem HBr and its financial position.
Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. Limbach said it sees FY24 revenue of $510 million to $530 million, versus market estimates of $541.1 million. Limbach shares dipped 14.7% to $42.42 o...
U.S. stocks finish sharply higher Friday after a softer-than-expected reading on February inflation.
Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.